Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluating Newly Approved Drugs for Multidrug-resistant TB (endTB): A Clinical Trial
Brief Summary: endTB Clinical Trial a Phase III, randomized, controlled, open-label, non-inferiority, multi-country trial evaluating the efficacy and safety of five new, all-oral, shortened regimens for multidrug-resistant tuberculosis (MDR-TB).


Options:
A: Arm Label: Bedaquiline + PA-824 + Linezolid; Type: EXPERIMENTAL; Interventions: Drug: Bedaquiline, Drug: PA-824, Drug: Linezolid | Intervention Type: DRUG; Name: Bedaquiline; Assigned to Arm(s): Bedaquiline + PA-824 + Linezolid | Intervention Type: DRUG; Name: PA-824; Assigned to Arm(s): Bedaquiline + PA-824 + Linezolid | Intervention Type: DRUG; Name: Linezolid; Assigned to Arm(s): Bedaquiline + PA-824 + Linezolid
B: Arm Label: Regimen 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: control | Arm Label: Regimen 2; Type: EXPERIMENTAL; Interventions: Drug: rifapentine | Arm Label: Regimen 3; Type: EXPERIMENTAL; Interventions: Drug: rifapentine and moxifloxacin | Intervention Type: DRUG; Name: rifapentine; Assigned to Arm(s): Regimen 2 | Intervention Type: DRUG; Name: rifapentine and moxifloxacin; Assigned to Arm(s): Regimen 3 | Intervention Type: DRUG; Name: control; Assigned to Arm(s): Regimen 1
C: Arm Label: Rifampicin resistant and susceptible patients; Type: N/A; Interventions: Diagnostic Test: Deeplex test, MolBio TrueNat for 2nd line, GeneXpert 2nd line | Arm Label: Rifampicin resistant patients; Type: N/A; Interventions: Diagnostic Test: Fluorescein DiAcetate (FDA) Microscopy,GeneXpert Ct value, pre-rRNA synthesis | Intervention Type: DIAGNOSTIC_TEST; Name: Deeplex test, MolBio TrueNat for 2nd line, GeneXpert 2nd line; Assigned to Arm(s): Rifampicin resistant and susceptible patients | Intervention Type: DIAGNOSTIC_TEST; Name: Fluorescein DiAcetate (FDA) Microscopy,GeneXpert Ct value, pre-rRNA synthesis; Assigned to Arm(s): Rifampicin resistant patients
D: Arm Label: endTB regimen 1 (BeLiMoZ); Type: EXPERIMENTAL; Interventions: Drug: Bedaquiline, Drug: Moxifloxacin, Drug: Linezolid, Drug: Pyrazinamide | Arm Label: endTB regimen 2 (BeLiCLeZ); Type: EXPERIMENTAL; Interventions: Drug: Bedaquiline, Drug: Clofazimine, Drug: Levofloxacin, Drug: Linezolid, Drug: Pyrazinamide | Arm Label: endTB regimen 3 (BeDeLiLeZ); Type: EXPERIMENTAL; Interventions: Drug: Bedaquiline, Drug: Delamanid, Drug: Levofloxacin, Drug: Linezolid, Drug: Pyrazinamide | Arm Label: endTB regimen 4 (DeLiCLeZ); Type: EXPERIMENTAL; Interventions: Drug: Delamanid, Drug: Clofazimine, Drug: Levofloxacin, Drug: Linezolid, Drug: Pyrazinamide | Arm Label: endTB regimen 5 (DeCMoZ); Type: EXPERIMENTAL; Interventions: Drug: Delamanid, Drug: Clofazimine, Drug: Moxifloxacin, Drug: Pyrazinamide | Arm Label: endTB regimen 6 (Control); Type: ACTIVE_COMPARATOR; Interventions: Drug: Control arm MDR-TB regimen, consistent with WHO guidelines | Intervention Type: DRUG; Name: Bedaquiline; Assigned to Arm(s): endTB regimen 1 (BeLiMoZ), endTB regimen 2 (BeLiCLeZ), endTB regimen 3 (BeDeLiLeZ) | Intervention Type: DRUG; Name: Delamanid; Assigned to Arm(s): endTB regimen 3 (BeDeLiLeZ), endTB regimen 4 (DeLiCLeZ), endTB regimen 5 (DeCMoZ) | Intervention Type: DRUG; Name: Clofazimine; Assigned to Arm(s): endTB regimen 2 (BeLiCLeZ), endTB regimen 4 (DeLiCLeZ), endTB regimen 5 (DeCMoZ) | Intervention Type: DRUG; Name: Levofloxacin; Assigned to Arm(s): endTB regimen 2 (BeLiCLeZ), endTB regimen 3 (BeDeLiLeZ), endTB regimen 4 (DeLiCLeZ) | Intervention Type: DRUG; Name: Moxifloxacin; Assigned to Arm(s): endTB regimen 1 (BeLiMoZ), endTB regimen 5 (DeCMoZ) | Intervention Type: DRUG; Name: Linezolid; Assigned to Arm(s): endTB regimen 1 (BeLiMoZ), endTB regimen 2 (BeLiCLeZ), endTB regimen 3 (BeDeLiLeZ), endTB regimen 4 (DeLiCLeZ) | Intervention Type: DRUG; Name: Pyrazinamide; Assigned to Arm(s): endTB regimen 1 (BeLiMoZ), endTB regimen 2 (BeLiCLeZ), endTB regimen 3 (BeDeLiLeZ), endTB regimen 4 (DeLiCLeZ), endTB regimen 5 (DeCMoZ) | Intervention Type: DRUG; Name: Control arm MDR-TB regimen, consistent with WHO guidelines; Assigned to Arm(s): endTB regimen 6 (Control)

Answer: D